Impact of Osmotically Active Excipients on Bioavailability and Bioequivalence of BCS Class III Drugs
The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has been widely used to predict drug absorption during pharmaceutical development (1). Recently, the system has also been employed in regulatory practice to determine if waiver of in vivo bioavailability or bioequivalence studies (i.e., biowaivers) can be granted for an immediate-release solid oral dosage form (2). In this regard, the US Food and Drug Administration (FDA) currently allows biowaivers for BCS class I (highly soluble and highly permeable) drugs formulated in immediate release, rapidly dissolving drug products (2). Since the publication of the FDA Guidance on BCS in 2000, however, there has been continued interest in the possible extension of BCS-based biowaivers, particularly for class III drugs that exhibit high solubility and low permeability (3, 4, 5).
One of the major challenges to the allowance of biowaivers for BCS class III drugs is related to the...
Key wordsBCS bioavailability/bioequivalence drug absorption excipient osmotic potential
- 2.U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. August 2000. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf. Accessed 9 Aug 2012.
- 7.Rowe RC, Sheskey PJ, Cook WG, Fenton ME. Handbook of pharmaceutical excipients. 7th ed. London: Pharmaceutical Press; 2012.Google Scholar
- 21.U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Labeling and Program Support, Office of Generic Drugs. Inactive ingredient search for approved drug products. http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm. Accessed 13 Aug 2012
- 25.Niwa H, Hikichi N, Sakurai E, Ueda M, Fukush G. Effects of maltitol or mannitol on gastrointestinal absorption of drugs. Yakugaku Zasshi J Pharm Soc. 1980;100:1118–26.Google Scholar
- 29.Yalkowsky SH. Techniques of solubilization of drugs. New York: Marcel Dekker; 1981.Google Scholar
- 40.Evaluation of the health aspects of phosphates as food ingredients. Report PB-262 651, Life Sciences Research Office, Fed Am Soc Exp Biol. 1975.Google Scholar
- 42.Title 21 Code of Federal Regulations (CFR) Part 320.22, Office of Federal Register, National Archives and Records Administration, US Government Printing Office, Washington, 2011.Google Scholar
- 43.US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products—general considerations. March 2003. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf. Accessed 16 Aug 2012.
- 45.Guyton AC, Hall JE. Textbook of medical pysiology. 9th ed. Philadelphia: Saunders; 1996.Google Scholar